Honorary Professor of Medicine and Consultant Physician,
David Baldwin works as a consultant respiratory physician sub-specialising in lung cancer and mesothelioma and interventional procedures. He is Chair of the Clinical Expert Group for Lung Cancer, NHS England and Clinical Director of the East Midlands Cancer Alliance. He is Honorary Professor in the School of Medicine at the University of Nottingham. He has obtained research grants from a variety of charities and NIHR. His primary research interests are in CT screening and lung cancer epidemiology. He is lead respiratory physician on the UK CT lung cancer screening trial (UKLS). He has published over 190 papers. He has held the positions of Honorary Secretary of the British Thoracic Society, Clinical Lead on the NICE Lung Cancer Guideline Development Group and Chair of the Quality Standards Group on Lung Cancer. He works with Public Health England and the National Cancer Research Institute and is Chair of the Screening Prevention and Early Diagnosis Group. He enjoys time with his family and is a keen windsurfer and advanced instructor.
I completed 11 years of post-graduate training and became accredited in general medicine and respiratory medicine in 1996. As a consultant, I practised general (internal) medicine and respiratory medicine until 2011 and now limit this to respiratory medicine. I am based at Nottingham University Hospitals (City Campus). I have experience in all areas of respiratory medicine and have a special interest in lung cancer, pleural disease, and interventional bronchoscopy and thoracoscopy.
Continuing Professional Development
I have registered and completed the CPD record for the Royal College of Physicians since its inception. I continue to comply with CPD requirements with local, national, and international educational activities. As part of my CPD I have attended local courses on counselling (level 1-3), equal opportunities, leading and managing change, teaching improvement, senior management training, Clinical Tutor training, mandatory Trust training, National Cancer Action Team Advanced Communication skills course and Good Clinical Practice (research).
I have a broad-based background in medical research, encompassing aspects of asthma pathophysiology, epidemiology, occupational asthma, pulmonary infection, cystic fibrosis, information technology in medicine, lung cancer and a number of smaller projects.
Lung Cancer Research
Over the last 7 years my main research focus has been on lung cancer. I am now involved with a number of important research projects that link with some of my external, national duties.
Screening for Lung Cancer
I am co-applicant and lead respiratory physician on a large national study on CT screening for lung cancer (UK Lung Screen) funded by the NIHR HTA programme. This has just completed the pilot study that has recruited 4000 subjects. There is likely to be considerable benefit in screening for lung cancer and this study will help the design of cost effective programmes. I am coapplicant on a lung cancer screening trial at UCL looking at aspects of recruitment of the hard to reach. I am also co-applicant in the Yorkshire Screening Trial (funded for £5.2 million)
Epidemiology and Health Services Research
I have been working in collaboration with Professor Richard Hubbard, Division of Epidemiology and Public Health on a number of projects employing large datasets to answer some key questions. This involves the co-supervision of one DM and 3 PhD Fellows. I also provide clinical training. This has resulted in a number of successful grant applications and several publications. This working is now look at all aspects of the lung cancer pathway and the research team is growing to include more members of the multidisciplinary team. Nottingham now has a national reputation for its contribution to research in this area.
Other lung cancer research
I am an investigator in a number of studies including MesoVATS, Fragmatic and BOOST all funded by non-pharma sources. I have an active role on research design and steering committees. Three recent examples are: Prophylactic radiotherapy in Tracts (mesothelioma) - successful funding based at Christie Hospital Manchester; Surgery or SABR for patients with borderline fitness (re-application in progress); and Early palliative care in lung cancer (unsuccessful; high rating by HTA). I have also been involved in studies of biomarkers in lung cancer. I am principal investigator for NUH on the Sputnik trial and SABRTooTH trials.
I have been actively involved in teaching and training at undergraduate and postgraduate level. In the latter I have held a number of posts at regional and national level including advice to… read more
Epidemiology of lung cancer
Diagnostic and staging clinical pathways in lung cancer
Early diagnosis of lung cancer
CT screening for lung cancer
BALDWIN DR, HANSELL DM, DUFFY SW and FIELD JK, 2014. Lung cancer screening with low dose computed tomography. BMJ (Clinical research ed.). 348, g1970
POWELL HA, IYEN-OMOFOMAN B, HUBBARD RB, BALDWIN DR and TATA LJ, 2013. The association between smoking quantity and lung cancer in men and women. Chest. 143(1), 123-9
BALDWIN DR, WHITE B, SCHMIDT-HANSEN M, CHAMPION AR, MELDER AM and GUIDELINE DEVELOPMENT GROUP, 2011. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ (Clinical research ed.). 342, d2110
BALDWIN, D. R., DUFFY, S. W., WALD, N. J., PAGE, R., HANSELL, D. M. and FIELD, J. K., 2010. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer THORAX. 66(4), 308-313
I have been actively involved in teaching and training at undergraduate and postgraduate level. In the latter I have held a number of posts at regional and national level including advice to government.
I teach CP3 and CP 5 medical students for an hour each week. I lecture on the CP5 programme. Between 1996 and 2001 I sat on the Medical and Surgical Working Party, a working group supporting the Curriculum Committee. I have previously mentored student and have promoted respiratory medicine at several student careers events. I am a contact for careers advice in the student handbook.
I held the post of RCP District Tutor (College Tutor) from 1997 to 2002 and during this time developed a regular system of protected education sessions covering a general medical curriculum (similar to the now well-established Core Medical Training curriculum). I also created a new training programme for PACES. During this time and after, I hosted the PACES examination at NUH. I lectured at the RCP and at several hospitals on the development of a teaching programme for SHOs. I became assistant regional advisor in 1999 and continued until 2002.
I became Director of Postgraduate Medical Education in 2003 and continued until 2009. During this time I redeveloped the support system provide by the education centre in line with the national development in education including the need for more support for educational supervision and formalised teaching. I wrote the first (in the country) Trust Strategy for Postgraduate Medical Education and this was used as a template at several other NHS Trusts. I became Chair of the regional Clinical Tutors and Medical Education Managers in 2004 and continued until 2009. I was a council member on the National Association of Clinical Tutors and in this role was involved in several advisory roles involving the Department of Health. I was an active member of several Deanery based committees (see committees below).
I developed several teaching courses including teaching days on respiratory medicine, interventional bronchoscopy and lung cancer. As College Tutor I developed an acute medicine course and since then NUH became of the first sites to offer the Federation of Colleges of Physicians and Anaesthetists accredited course "IMPACT" (Ill Medical Patient Acute Care and Treatment) RCP and RCS accredited. I made contributions to the written material and am acknowledged in the manual. I now direct 1 to 2 courses per year and run 1 to 2 instructor training courses per year.
I provide educational and clinical supervision to junior doctors at all levels. At any one time the amounts to 1 to 3 foundation doctors, 2 core medical training and one registrar. I also co-supervise 3 PhD students and was co-supervisor to three students one who obtained a DM from the University of Nottingham and two who obtained PhDs. My supervisory role includes research supervision and advanced clinical and management training.
National and Local Duties to Support Lung Cancer and Respiratory Medicine
I have a number of key roles that fit with my overall aim to improve the care of lung cancer patients and respiratory patients in general.
I am Chair of the Clinical Reference Group for Lung cancer for NHS England (2014- ). This is the key advisory group to NHSE and has been responsible for producing the service specification for lung cancer. The group advised NHS England on all matters relating to lung cancer. The group has an important role in providing expert advice to the CRUK/Macmillan ACE programme.
I am Lead for the East Midlands Strategic Clinical Network Lung Cancer Expert Clinical Advisory Group. This role involves regional implementation of best practice through implementation of guidelines, audit and research.
I was Honorary Secretary to the British Thoracic Society (BTS from 2009-13). This position involved supporting the important role of the BTS and brought me into contact with policy makers in the Department of Health.
I attended a variety of committees including the DH advisory Group on lung cancer and mesothelioma, Lung Cancer Awareness Month and was Chair of the BTS Lung Cancer and Mesothelioma Specialist Advisory Group for 4 years until December 2009. The latter has proved an influential group. It has overseen the production of the BTS Mesothelioma Statement and the forth-coming BTS guidelines for fitness for radical treatment as well as commenting on numerous documents. As Chair I have been involved with much of the work.
I support the work of an NHS Improvement Foundation Pilot (that was discussed at meetings I attended at the DH at an early stage) in Nottingham that is training volunteers to teach others about awareness of early symptoms of lung, breast and bowel cancer. I am on the steering group and run workshops (both in Nottingham and other pilots).
I am a member of the National Cancer Research Institute (NCRI) lung Cancer Group and the Screening Prevention and Early Diagnosis Group (set up in 2012). Both of these groups are influential in planning and supporting lung cancer and cancer research.
NATIONAL INSTITUTE FOR HEALTH AN CLINICAL EXCELLENCE
I was Clinical Lead in the NICE management of Lung Cancer Guideline Update, published in April 2011. The guideline was well received. Subsequently I chaired the NICE quality standard Topic expert Group and the Standard was published in March 2012. Draft Commissioning Outcomes Framework indicators have now been submitted to NICE. This has been an excellent opportunity to work with committed colleagues to encourage better standards of care for lung cancer. As a busy clinician, I have found it easy to prioritise subjects into those most likely to make the most difference.
I was a NICE Fellow from 2012 to 2015, which allowed me to learn more about the process of implementation and the growing science behind it. This has enabled me to encourage the commissioning of services that can deliver the standards that have been set.
United Kingdom Lung Cancer CT Screening Study (UKLS).
NIHR HTA, 2010-11
NIHR HTA, 2011-2014
Analysis of the National Lung Cancer Audit
(to host a DM Fellow with Prof Hubbard)
Royal College of
Analysis of multiple datasets to look at aspects of risk of death from lung cancer
University of Nottingham Biomedical Research
Analysis of factors predicting emergency admission to hospitals and outcome.
Roy Castle Foundation 2013-2016
Prophylactic Irradiation of Tracts
Christie Hospital (RFPB) 2012-PB-PG-1010-23232
Pilot study of metabolomics biomarkers
NUH NHS R&D 2009-
Developing and testing targeted invitation materials to increase uptake of lung cancer screening in communities at high risk of lung cancer
National Awareness and Early Diagnosis Initiative April 2014-
A study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of complications from surgical resection.
National Institute for Health Research (NIHR)
Research for Patient Benefit (RfPB) [PB-PG-0613-31114] August 2014-
Grant Status (Asc)
Primary Staff Contact
Nottingham University Hospitals NHS Trust
SELECT Selection of Eligible People for Lung Cancer Screening using Electronic Primary Care DaTa: Development of new risk prediction models
Yorkshire Lung Cancer Screening Trial
Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX)
CRUK Early Diagnosis Advisory Group
Artificial Intelligence and Big Data for Early Lung Cancer Diagnosis
National Institute for Health Research (NIHR)
Invention for Innovation (i4i) 2017-
FaHRAS Cancer Risk Assessment Software
The effect of adding a personalised smoking cessation intervention to a lung cancer screening programme.
Methods for prevention and early detection of lung cancer after Hodgkin-lymphoma treatment
Roy Castle Lung Cancer Foundation
Impact on Quality of life from multi-modality treatment for lung cancer: A randomised controlled feasibility trial of surgery versus radiotherapy in addition to systemic anti-cancer therapy in potentially resectable Stage III-N2 NSCLC
Readiness of lung cancer screening services to deliver concurrent smoking cessation treatment: Guideline and implementation toolkit development
CRUK Tobacco Advisory Group - Project Award C63992/A27905
Co-applicant, PI Local
The integration and analysis of data using artificial intelligence to improve patient outcomes with thoracic diseases (DART)
JONES GS, ELIMIAN K, BALDWIN DR, HUBBARD RB and MCKEEVER TM, 2020. A systematic review of survival following anti-cancer treatment for small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 141, 44-55 BALDWIN DR, GUSTAFSON J, PICKUP L, ARTETA C, NOVOTNY P, DECLERCK J, KADIR T, FIGUEIRAS C, STERBA A, EXELL A, POTESIL V, HOLLAND P, SPENCE H, CLUBLEY A, O'DOWD E, CLARK M, ASHFORD-TURNER V, CALLISTER ME and GLEESON FV, 2020. External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules. Thorax. 75(4), 306-312 PERROTTA F, NANKIVELL M, ADIZIE B, MAQSOOD U, ELSHAFI M, JAFRI S, LERNER AD, WOOLHOUSE I, MUNAVVAR M, EVISON M, BOOTON R, BALDWIN DR, JANES SM, KERR KM, BIANCO A, YARMUS L and NAVANI N, 2020. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing In Non-Small Cell Lung Cancer. Chest.
RUPAREL M, QUAIFE SL, DICKSON JL, HORST C, TISI S, HALL H, TAYLOR MN, AHMED A, SHAW PJ, BURKE S, SOO MJ, NAIR A, DEVARAJ A, SENNETT K, HURST JR, DUFFY SW, NAVANI N, BHOWMIK A, BALDWIN DR and JANES SM, 2020. Prevalence, Symptom Burden and Under-Diagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort. Annals of the American Thoracic Society.
MORGAN, HELEN, O'DOWD, EMMA L., NAIR, ARJUN and BALDWIN, DAVID R., 2020. New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study? Comment TRANSLATIONAL LUNG CANCER RESEARCH. 9(5), 2161-2164
AU-YONG, I. T. H., HAMILTON, W., RAWLINSON, J. and BALDWIN, D. R., 2020. Pulmonary nodules BMJ-BRITISH MEDICAL JOURNAL. 371, OKE JL, PICKUP LC, DECLERCK J, CALLISTER ME, BALDWIN D, GUSTAFSON J, PESCHL H, ATHER S, TSAKOK M, EXELL A and GLEESON F, 2019. Development and validation of clinical prediction models to risk stratify patients presenting with small pulmonary nodules: a research protocol. Diagnostic and prognostic research. 2, 22 RICH A, BECKETT P and BALDWIN D, 2019. Status of Lung Cancer Data Collection in Europe. JCO clinical cancer informatics. 2, 1-12 QUAIFE SL, RUPAREL M, DICKSON JL, BEEKEN RJ, MCEWEN A, BALDWIN DR, BHOWMIK A, NAVANI N, SENNETT K, DUFFY SW, WALLER J and JANES SM, 2019. Lung Screen Uptake Trial (LSUT): Randomised Controlled Trial Testing Targeted Invitation Materials. American journal of respiratory and critical care medicine.
RUPAREL M, QUAIFE S, BALDWIN D, WALLER J and JANES S, 2019. Defining the information needs of lung cancer screening participants: a qualitative study. BMJ open respiratory research. 6(1), e000448 RUPAREL M, QUAIFE SL, DICKSON JL, HORST C, BURKE S, TAYLOR M, AHMED A, SHAW P, SOO MJ, NAIR A, DEVARAJ A, O'DOWD EL, BHOWMIK A, NAVANI N, SENNETT K, DUFFY SW, BALDWIN DR, SOFAT R, PATEL RS, HINGORANI A and JANES SM, 2019. Evaluation of cardiovascular risk in a lung cancer screening cohort. Thorax. 74(12), 1140-1146 BAYMAN N, APPEL W, ASHCROFT L, BALDWIN DR, BATES A, DARLISON L, EDWARDS JG, EZHIL V, GILLIGAN D, HATTON M, JEGANNATHEN A, MANSY T, PEAKE MD, PEMBERTON L, RINTOUL RC, SNEE M, RYDER WD, TAYLOR P and FAIVRE-FINN C, 2019. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(14), 1200-1208 SOO E, EDEY AJ, MAK SM, MOSER J, MOHAMMADI S, RODRIGUES T, DUFFY SW, FIELD JK, BALDWIN DR, NAIR A and DEVARAJ A, 2019. Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening. European journal of radiology. 120, 108646 RUPAREL M, QUAIFE SL, GHIMIRE B, DICKSON JL, BHOWMIK A, NAVANI N, BALDWIN DR, DUFFY S, WALLER J and JANES SM, 2019. Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial. Annals of the American Thoracic Society. 16(6), 744-751 RICH AL, BALDWIN DR, BECKETT P, BERGHMANS T, BOYD J, FAIVRE-FINN C, GALATEAU-SALLE F, GAMARRA F, GRIGORIU B, HANSEN NG, HARDAVELLA G, JAKOBSEN E, JOVANOVIC D, KONSOULOVA A, MASSARD G, MCPHELIM J, MEERT AP, MILROY R, MUTTI L, PAESMANS M, PEAKE MD, PUTORA PM, DE RUYSSCHER DKM, SCULIER JP, SCHERPEREEL A, SUBOTIC DR, VAN SCHIL P and BLUM TG, 2018. ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. The European respiratory journal. 52(6), FIELD JK, BALDWIN DR, DEVARAJ A and OUDKERK M, 2018. EUPS-argues that lung cancer screening should be implemented in 18 months. The British journal of radiology. 91(1090), 20180243 JONES GS and BALDWIN DR, 2018. Recent advances in the management of lung cancer. Clinical medicine (London, England). 18(Suppl 2), s41-s46 RICH A, BALDWIN D, ALFAGEME I, BECKETT P, BERGHMANS T, BRINCAT S, BURGHUBER O, CORLATEANU A, CUFER T, DAMHUIS R, DANILA E, DOMAGALA-KULAWIK J, ELIA S, GAGA M, GOKSEL T, GRIGORIU B, HILLERDAL G, HUBER RM, JAKOBSEN E, JONSSON S, JOVANOVIC D, KAVCOVA E, KONSOULOVA A, LAISAAR T, MAKITARO R, MEHIC B, MILROY R, MOLDVAY J, MORGAN R, NANUSHI M, PAESMANS M, PUTORA PM, SAMARZIJA M, SCHERPEREEL A, SCHLESSER M, SCULIER JP, SKRICKOVA J, SOTTO-MAYOR R, STRAND TE, VAN SCHIL P and BLUM TG, 2018. Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries. BMC cancer. 18(1), 1144 HIOM SC, KUMAR HS, SWANTON C, BALDWIN DR and PEAKE MD, 2018. Lung cancer in the UK: addressing geographical inequality and late diagnosis. The Lancet. Oncology. 19(8), 1015-1017 BALDWIN D, CALLISTER M, AKRAM A, CANE P, DRAFFAN J, FRANKS K, GLEESON F, GRAHAM R, MALHOTRA P, PEARSON P, SUBESINGHE M, WALLER D and WOOLHOUSE I, 2018. British Thoracic Society quality standards for the investigation and management of pulmonary nodules. BMJ open respiratory research. 5(1), e000273 MØLLER H, COUPLAND VH, TATARU D, PEAKE MD, MELLEMGAARD A, ROUND T, BALDWIN DR, CALLISTER MEJ, JAKOBSEN E, VEDSTED P, SULLIVAN R and SPICER J, 2018. Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients. Thorax. 73(6), 530-537 FIELD JK, HEUVELMANS MA, DEVARAJ A, HEUSSEL CP, BALDWIN DR, VLIEGENTHART R, DUFFY SW and OUDKERK M, 2018. Low-dose CT for lung cancer screening - Authors' reply. The Lancet. Oncology. 19(3), e135-e136 HIOM, SARA C., KUMAR, HARPAL S., SWANTON, CHARLES, BALDWIN, DAVID R. and PEAKE, MICHAEL D., 2018. Lung cancer in the UK: addressing geographical inequality and late diagnosis LANCET ONCOLOGY. 19(8), 1015-1017 AWAN S, CROSBY V, POTTER V, HENNIG I, BALDWIN D, NDLOVU M, PARADINE S and WILCOCK A, 2017. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. Lung cancer (Amsterdam, Netherlands). 104, 75-78 OUDKERK M, DEVARAJ A, VLIEGENTHART R, HENZLER T, PROSCH H, HEUSSEL CP, BASTARRIKA G, SVERZELLATI N, MASCALCHI M, DELORME S, BALDWIN DR, CALLISTER ME, BECKER N, HEUVELMANS MA, RZYMAN W, INFANTE MV, PASTORINO U, PEDERSEN JH, PACI E, DUFFY SW, DE KONING H and FIELD JK, 2017. European position statement on lung cancer screening. The Lancet. Oncology. 18(12), e754-e766 NAIR A, SCREATON NJ, HOLEMANS JA, JONES D, CLEMENTS L, BARTON B, GARTLAND N, DUFFY SW, BALDWIN DR, FIELD JK, HANSELL DM and DEVARAJ A, 2017. The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial. European radiology. 28(1), 226-234 DEVARAJ A, VAN GINNEKEN B, NAIR A and BALDWIN D, 2017. Use of Volumetry for Lung Nodule Management: Theory and Practice. Radiology. 284(3), 630-644 SCHMIDT-HANSEN M, BERENDSE S, HAMILTON W and BALDWIN DR, 2017. Lung cancer in symptomatic patients presenting in primary care: a systematic review of risk prediction tools. The British journal of general practice : the journal of the Royal College of General Practitioners. 67(659), e396-e404 FIELD, J. K., ZULUETA, J., VERONESI, G., OUDKERK, M., BALDWIN, D. R., HOLST PEDERSEN, J., PACI, E., HORGAN, D. and DE KONING, H. J., 2017. EU Policy on Lung Cancer CT Screening 2017: Biomedicine Hub Biomedicine Hub. 2(suppl 1)(Suppl. 1), 10-10 O'DOWD, E. L., LUCHTENBORG, M., BALDWIN, D. R., MCKEEVER, T. M., POWELL, H. A., MOLLER, H., JAKOBSEN, E. and HUBBARD, R. B., 2016. Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries: Lung Cancer Lung Cancer. 95, 88-93 WALKER AJ, BALDWIN DR, CARD TR, POWELL HA, HUBBARD RB and GRAINGE MJ, 2016. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. British journal of cancer. 115(1), 115-21 SNEE MP, MCPARLAND L, COLLINSON F, LOWE CM, STRIHA A, BALDWIN DR, NAIDU B, SEBAG-MONTEFIORE D, GREGORY WM, BESTALL J, HEWISON J, HINSLEY S and FRANKS KN, 2016. Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Pilot and feasibility studies. 2, 55 FIELD JK, DUFFY SW, DEVARAJ A and BALDWIN DR, 2016. Implementation planning for lung cancer screening: five major challenges. The Lancet. Respiratory medicine. 4(9), 685-7 BALDWIN DR and CALLISTER ME, 2016. What is the Optimum Screening Strategy for the Early Detection of Lung Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 28(11), 672-681 NAIR A, GARTLAND N, BARTON B, JONES D, CLEMENTS L, SCREATON NJ, HOLEMANS JA, DUFFY SW, FIELD JK, BALDWIN DR, HANSELL DM and DEVARAJ A, 2016. Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial. The British journal of radiology. 89(1066), 20160301 MAK KS, VAN BOMMEL AC, STOWELL C, ABRAHM JL, BAKER M, BALDOTTO CS, BALDWIN DR, BORTHWICK D, CARBONE DP, CHEN AB, FOX J, HASWELL T, KOCZYWAS M, KOZOWER BD, MEHRAN RJ, SCHRAMEL FM, SENAN S, STIRLING RG, VAN MEERBEECK JP, WOUTERS MW, PEAKE MD and , 2016. Defining a standard set of patient-centred outcomes for lung cancer. The European respiratory journal. 48(3), 852-60 FIELD JK, DUFFY SW, BALDWIN DR, BRAIN KE, DEVARAJ A, EISEN T, GREEN BA, HOLEMANS JA, KAVANAGH T, KERR KM, LEDSON M, LIFFORD KJ, MCRONALD FE, NAIR A, PAGE RD, PARMAR MK, RINTOUL RC, SCREATON N, WALD NJ, WELLER D, WHYNES DK, WILLIAMSON PR, YADEGARFAR G and HANSELL DM, 2016. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health technology assessment (Winchester, England). 20(40), 1-146 QUAIFE SL, RUPAREL M, BEEKEN RJ, MCEWEN A, ISITT J, NOLAN G, SENNETT K, BALDWIN DR, DUFFY SW, JANES SM and WARDLE J, 2016. The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients. BMC cancer. 16, 281 RUPAREL M, QUAIFE SL, NAVANI N, WARDLE J, JANES SM and BALDWIN DR, 2016. Pulmonary nodules and CT screening: the past, present and future. Thorax. 71(4), 367-75 BAYMAN N, ARDRON D, ASHCROFT L, BALDWIN DR, BOOTON R, DARLISON L, EDWARDS JG, LANG-LAZDUNSKI L, LESTER JF, PEAKE M, RINTOUL RC, SNEE M, TAYLOR P, LUNT C and FAIVRE-FINN C, 2016. Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ open. 6(1), e010589 RICH AL, KHAKWANI A, FREE CM, TATA LJ, STANLEY RA, PEAKE MD, HUBBARD RB and BALDWIN DR, 2015. Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit. QJM : monthly journal of the Association of Physicians. 108(11), 891-897 POWELL HA, JONES LL, BALDWIN DR, DUFFY JP, HUBBARD RB, TOD AM, TATA LJ, SOLOMON J and BAINS M, 2015. Patients' attitudes to risk in lung cancer surgery: A qualitative study. Lung cancer (Amsterdam, Netherlands). 90(2), 358-63 CALLISTER ME and BALDWIN DR, 2015. How should pulmonary nodules be optimally investigated and managed? Lung cancer (Amsterdam, Netherlands). 91, 48-55 FIELD JK, DEVARAJ A, DUFFY SW and BALDWIN DR, 2015. CT screening for lung cancer: Is the evidence strong enough? Lung cancer (Amsterdam, Netherlands). 91, 29-35 FIELD JK, DUFFY SW, BALDWIN DR, WHYNES DK, DEVARAJ A, BRAIN KE, EISEN T, GOSNEY J, GREEN BA, HOLEMANS JA, KAVANAGH T, KERR KM, LEDSON M, LIFFORD KJ, MCRONALD FE, NAIR A, PAGE RD, PARMAR MK, RASSL DM, RINTOUL RC, SCREATON NJ, WALD NJ, WELLER D, WILLIAMSON PR, YADEGARFAR G and HANSELL DM, 2015. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 71(2), 161-70
JONES GS and BALDWIN DR, 2015. Lung cancer screening and management. Minerva medica. 106(6), 339-54
RAKHA E, PAJARES MJ, ILIE M, PIO R, ECHEVESTE J, HUGHES E, SOOMRO I, LONG E, IDOATE MA, WAGNER S, LANCHBURY JS, BALDWIN DR, HOFMAN P and MONTUENGA LM, 2015. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. European journal of cancer (Oxford, England : 1990). 51(14), 1897-903 ALI N, LIFFORD KJ, CARTER B, MCRONALD F, YADEGARFAR G, BALDWIN DR, WELLER D, HANSELL DM, DUFFY SW, FIELD JK and BRAIN K, 2015. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ open. 5(7), e008254 CALLISTER ME, BALDWIN DR, AKRAM AR, BARNARD S, CANE P, DRAFFAN J, FRANKS K, GLEESON F, GRAHAM R, MALHOTRA P, PROKOP M, RODGER K, SUBESINGHE M, WALLER D, WOOLHOUSE I, and , 2015. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 70 Suppl 2, ii1-ii54 NAVANI N, NANKIVELL M, LAWRENCE DR, LOCK S, MAKKER H, BALDWIN DR, STEPHENS RJ, PARMAR MK, SPIRO SG, MORRIS S, JANES SM and , 2015. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. The Lancet. Respiratory medicine. 3(4), 282-9
O'DOWD EL and BALDWIN DR, 2015. Early diagnosis pivotal to survival in lung cancer. The Practitioner. 258(1776), 21-4, 2-3
POWELL HA, TATA LJ, BALDWIN DR, POTTER VA, STANLEY RA, KHAKWANI A and HUBBARD RB, 2014. Treatment decisions and survival for people with small-cell lung cancer. British journal of cancer. 110(4), 908-915
BALDWIN DR, 2014. Effective lung cancer screening is possible. BMJ (Clinical research ed.). 348, g363
FIELD JK, ABERLE DR, ALTORKI N, BALDWIN DR, DRESLER C, DUFFY SW, GOLDSTRAW P, HIRSCH FR, PEDERSEN JH, DE KONING HJ, MULSHINE JL, SULLIVAN DC, TSAO M, TRAVIS WD and INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER STRATEGIC SCREENING ADVISORY COMMITTEE, 2014. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 9(2), 141-3 MCRONALD FE, YADEGARFAR G, BALDWIN DR, DEVARAJ A, BRAIN KE, EISEN T, HOLEMANS JA, LEDSON M, SCREATON NJ, RINTOUL RC, HANDS CJ, LIFFORD K, WHYNES DK, KERR KM, PAGE R, PARMAR M, WALD N, WELLER D, WILLIAMSON PR, MYLES J, HANSELL DM, DUFFY SW and FIELD JK, 2014. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer prevention research (Philadelphia, Pa.). KHAKWANI A, RICH AL, TATA LJ, POWELL HA, STANLEY RA, BALDWIN DR and HUBBARD RB, 2014. Small-cell lung cancer in England: trends in survival and chemotherapy using the national lung cancer audit. PloS one. 9(2), e89426
BALDWIN DR, HANSELL DM, DUFFY SW and FIELD JK, 2014. Lung cancer screening with low dose computed tomography. BMJ (Clinical research ed.). 348, g1970
BLUM TG, RICH A, BALDWIN D, BECKETT P, DE RUYSSCHER D, FAIVRE-FINN C, GAGA M, GAMARRA F, GRIGORIU B, HANSEN NCG, HUBBARD R, HUBER RM, JAKOBSEN E, JOVANOVIC D, KONSOULOVA A, KOLLMEIER J, MASSARD G, MCPHELIM J, MEERT A, MILROY R, PAESMANS M, PEAKE M, PUTORA P, SCHERPEREEL A, SCHÖNFELD N, SITTER H, SKAUG K, SPIRO S, STRAND T, TARIGHT S, THOMAS M, VAN SCHIL PE, VANSTEENKISTE JF, WIEWRODT R and SCULIER J, 2014. The European initiative for quality management in lung cancer care. The European respiratory journal. 43(5), 1254-77 KHAKWANI A, RICH AL, POWELL HA, TATA LJ, STANLEY RA, BALDWIN DR, DUFFY JP and HUBBARD RB, 2014. The impact of the 'hub and spoke' model of care for lung cancer and equitable access to surgery. Thorax. 70(2), 146-151
E O'DOWD and D BALDWIN, 2014. Early diagnosis pivotal to survival in lung cancer Practitioner. 258(1776), 21-4
O'DOWD EL, MCKEEVER TM, BALDWIN DR, ANWAR S, POWELL HA, GIBSON JE, IYEN-OMOFOMAN B and HUBBARD RB, 2014. What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? Thorax. 70(2), 161-8 LUECHTENBORG, MARGREET, RIAZ, SHARMA P., LIM, ERIC, PAGE, RICHARD, BALDWIN, DAVID R., JAKOBSEN, ERIK, VEDSTED, PETER, LIND, MIKE, PEAKE, MICHAEL D., MELLEMGAARD, ANDERS, SPICER, JAMES, LANG-LAZDUNSKI, LOIC and MOLLER, HENRIK, 2014. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009 THORAX. 69(3), 269-273 SCHMIDT-HANSEN M, BALDWIN DR, HASLER E, ZAMORA J, ABRAIRA V and ROQUÉ I FIGULS M, 2014. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. The Cochrane database of systematic reviews. CD009519 CHINUCK R, DEWAR J, BALDWIN DR and HENDRON E, 2014. Appetite stimulants for people with cystic fibrosis. The Cochrane database of systematic reviews. CD008190 CANNON RL, BALDWIN DR, DILORETO DJ, PHILLIPS ST, SHAW TL and LEVY JJ, 2014. LORETA Neurofeedback in the Precuneus: Operant Conditioning in Basic Mechanisms of Self-Regulation. Clinical EEG and neuroscience. 45(4), 238-248 KHAKWANI A, RICH AL, TATA LJ, POWELL HA, STANLEY RA, BALDWIN DR and HUBBARD RB, 2013. The pathological confirmation rate of lung cancer in England using the NLCA database. Lung cancer (Amsterdam, Netherlands). 79(2), 125-31 POWELL HA, IYEN-OMOFOMAN B, HUBBARD RB, BALDWIN DR and TATA LJ, 2013. The association between smoking quantity and lung cancer in men and women. Chest. 143(1), 123-9 POWELL HA, IYEN-OMOFOMAN B, BALDWIN DR, HUBBARD RB and TATA LJ, 2013. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 8(1), 6-11 IYEN-OMOFOMAN, B., TATA, L.J., BALDWIN, D.R., SMITH, C.J.P. and HUBBARD, R.B., 2013. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier Thorax. 68(5), 451-459 POWELL, H.A., TATA, L.J., BALDWIN, D.R., STANLEY, R.A., KHAKWANI, A. and HUBBARD, R.B., 2013. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit Thorax. 68(9), 826-834 KHAKWANI A, RICH AL, POWELL HA, TATA LJ, STANLEY RA, BALDWIN DR, DUFFY JP and HUBBARD RB, 2013. Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit. British journal of cancer.
POWELL HA, IYEN-OMOFOMAN B, BALDWIN DR, HUBBARD RB and TATA LJ, 2013. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 8(4), e34-5 FIELD JK, HANSELL DM, DUFFY SW and BALDWIN DR, 2013. CT screening for lung cancer: countdown to implementation. The lancet oncology. 14(13), e591-600
FIELD JK, BALDWIN D, BRAIN K, DEVARAJ A, EISEN T, DUFFY SW, HANSELL DM, KERR K, PAGE R, PARMAR M, WELLER D, WHYNES D and WILLIAMSON P, 2013. Authors' response. Thorax. 68(1), 105
NAIR A, BALDWIN DR, FIELD JK, HANSELL DM and DEVARAJ A, 2012. Measurement methods and algorithms for the management of solid nodules. Journal of thoracic imaging. 27(4), 230-9 SCHMIDT-HANSEN M, BALDWIN DR and HASLER E, 2012. What is the most effective follow-up model for lung cancer patients? A systematic review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 7(5), 821-4 FIELD JK, SMITH RA, ABERLE DR, OUDKERK M, BALDWIN DR, YANKELEVITZ D, PEDERSEN JH, SWANSON SJ, TRAVIS WD, WISBUBA II, NOGUCHI M, MULSHINE JL and IASLC CT SCREENING WORKSHOP 2011 PARTICIPANTS, 2012. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 7(1), 10-9 RICH, A.L., TATA, L.J., FREE, C.M., STANLEY, R.A., PEAKE, M.D., BALDWIN, D.R. and HUBBARD, R.B., 2011. How do patient and hospital features influence outcomes in small-cell lung cancer in England? British Journal of Cancer. 105(6), 746-752 RICH, A.L., TATA, L.J., FREE, C.M., STANLEY, R.A., PEAKE, M.D., BALDWIN, D.R. and HUBBARD, R.B., 2011. Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service Thorax. 66(12), 1078-1084
BALDWIN DR, 2011. Improving outcomes in lung cancer patients. The Practitioner. 255(1745), 19-22, 2
BALDWIN DR, WHITE B, SCHMIDT-HANSEN M, CHAMPION AR, MELDER AM and GUIDELINE DEVELOPMENT GROUP, 2011. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ (Clinical research ed.). 342, d2110
RICH, ANNA L, TATA, LAILA J, STANLEY, ROSAMUND A, FREE, CATHERINE M, PEAKE, MICHAEL D, BALDWIN, DAVID R and HUBBARD, RICHARD B, 2010. Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA). Lung cancer (Amsterdam, Netherlands). HUBBARD RB and BALDWIN DR, 2010. Diagnosing Lung Cancer Earlier In The Uk. Thorax. 65(9), 756-8 BALDWIN, D. R., DUFFY, S. W., WALD, N. J., PAGE, R., HANSELL, D. M. and FIELD, J. K., 2010. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer THORAX. 66(4), 308-313 CHAUHAN, ALPNA, SIDDALL, VANESSA, WILCOCK, ANDREW, MALLAWATHANTRI, SUGAMYA, BALDWIN, DAVID R and JOHNSTON, IAN D, 2007. NICE guidance for screening for malnutrition: implications for lung cancer services. Thorax. 62(9), 835 CHINUCK, R.S., FORTNUM, H. and BALDWIN, D.R., 2007. Appetite stimulants in cystic fibrosis: a systematic review. Journal of Human Nutrition and Dietetics. 20(6), 526-37 FREE CM, ELLIS M, BEGGS L, BEGGS D, MORGAN SA and BALDWIN DR, 2007. Lung cancer outcomes at a UK cancer unit between 1998-2001. Lung cancer (Amsterdam, Netherlands). 57(2), 222-8 BALDWIN DR, GANNON P, BRIGHT P, NEWTON DT, ROBERTSON A, VENABLES K, GRANEEK B, BARKER RD, CARTIER A, MALO J, WILSHER M, PANTIN CFA and BURGE PS, 2002. Interpretation of occupational peak flow records: level of agreement between expert clinicians and Oasys-2. Thorax. 57(10), 860-4 BALDWIN DR, EATON T, KOLBE J, CHRISTMAS T, MILNE D, MERCER J, STEELE E, GARRETT J, WILSHER ML and WELLS AU, 2002. Management of solitary pulmonary nodules: how do thoracic computed tomography and guided fine needle biopsy influence clinical decisions? Thorax. 57(9), 817-22 RODGERS HC, BALDWIN DR and KNOX AJ, 2000. Questionnaire survey of male infertility in cystic fibrosis. Respiratory medicine. 94(10), 1002-3
BURGE PS, PANTIN CF, NEWTON DT, GANNON PF, BRIGHT P, BELCHER J, MCCOACH J, BALDWIN DR and BURGE CB, 1999. Development of an expert system for the interpretation of serial peak expiratory flow measurements in the diagnosis of occupational asthma. Midlands Thoracic Society Research Group. Occupational and environmental medicine. 56(11), 758-64
LIM WS, MACFARLANE JT, DEEGAN PC, MANHIRE A, HOLMES WF and BALDWIN DR, 1999. How do general practitioners respond to reports of abnormal chest X-rays? Journal of the Royal Society of Medicine. 92(9), 446-9
BALDWIN DR, KOLBE J, TROY K, BELCHER J, GIBBS H, FRANKEL A, EATON T, CHRISTMAS T and VEALE A, 1998. Comparative clinical and physiological features of Maori, Pacific Islanders and Europeans with sleep related breathing disorders. Respirology (Carlton, Vic.). 3(4), 253-60
LAMONT J, BALDWIN DR, HAY KD and VEALE AG, 1998. Effect of two types of mandibular advancement splints on snoring and obstructive sleep apnoea. European journal of orthodontics. 20(3), 293-7
BALDWIN DR, BEECH CA, EVANS AH, PRESCOTT J, BRADBURY SP and PANTIN CF, 1997. Principals of design and evaluation of an information system for a department of respiratory medicine. Health care analysis : HCA : journal of health philosophy and policy. 5(1), 78-84
BALDWIN DR and ALLEN MB, 1997. Non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. BMJ (Clinical research ed.). 314(7075), 163-4
BALDWIN DR, LAMBERT L, PANTIN CF, PROWSE K and COLE RB, 1996. Silicosis presenting as bilateral hilar lymphadenopathy. Thorax. 51(11), 1165-7
BALDWIN DR, 1996. The penetration of novel intravenous cephalosporins into the lung. Journal of chemotherapy (Florence, Italy). 8 Suppl 2, 71-82
ANDREWS JM, WISE R, BALDWIN DR and HONEYBOURNE D, 1995. Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg oral dose. International journal of antimicrobial agents. 5(2), 141-4
PANTIN CF, KING R, PATHAK U, BALDWIN DR, BURGE PS and CUSHLEY MJ, 1995. Treating asthma. Scoring system developed for drug related morbidity. BMJ (Clinical research ed.). 310(6974), 255
HONEYBOURNE D, GREAVES I, BALDWIN DR, ANDREWS JM, HARRIS M and WISE R, 1994. The concentration of sparfloxacin in lung tissues after single and multiple oral doses. International journal of antimicrobial agents. 4(3), 151-5 BALDWIN DR, BALFOUR T and KNOX AJ, 1993. Laparoscopic cholecystectomy in patients with cystic fibrosis. Respiratory medicine. 87(3), 223-4
BALDWIN DR, GRANGE KL, PAVORD I and KNOX AJ, 1992. The effect of amiloride on the airway response to metabisulphite in asthma: a negative report. The European respiratory journal. 5(10), 1189-92
HONEYBOURNE D and BALDWIN DR, 1992. The site concentrations of antimicrobial agents in the lung. The Journal of antimicrobial chemotherapy. 30(3), 249-60 BALDWIN DR, WISE R, ANDREWS JM and HONEYBOURNE D, 1992. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. The Journal of antimicrobial chemotherapy. 30(1), 67-71 BALDWIN DR, WISE R, ANDREWS JM and HONEYBOURNE D, 1992. Quantitative morphology and water distribution of bronchial biopsy samples. Thorax. 47(7), 504-7 BALDWIN DR, HONEYBOURNE D and WISE R, 1992. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrobial agents and chemotherapy. 36(6), 1176-80 BALDWIN DR, HONEYBOURNE D and WISE R, 1992. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrobial agents and chemotherapy. 36(6), 1171-5
BALDWIN DR, WISE R, ANDREWS JM, ASHBY JP and HONEYBOURNE D, 1992. The distribution of temafloxacin in bronchial epithelial lining fluid, alveolar macrophages and bronchial mucosa. The European respiratory journal. 5(4), 471-6
WISE R, BALDWIN DR, ANDREWS JM and HONEYBOURNE D, 1991. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. The Journal of antimicrobial chemotherapy. 28 Suppl C, 65-71 COOPER MA, ANDREWS JM, BALDWIN DR, THORNBER D and WISE R, 1991. In-vitro activity and beta-lactamase stability of SR 44337, a new long acting cephalosporin. The Journal of antimicrobial chemotherapy. 28(2), 229-37 BALDWIN DR, MAXWELL SR, HONEYBOURNE D, ANDREWS JM, ASHBY JP and WISE R, 1991. The penetration of cefpirome into the potential sites of pulmonary infection. The Journal of antimicrobial chemotherapy. 28(1), 79-86
BALDWIN DR, WISE R, ANDREWS JM, ASHBY JP and HONEYBOURNE D, 1990. Azithromycin concentrations at the sites of pulmonary infection. The European respiratory journal. 3(8), 886-90
BALDWIN DR, HONEYBOURNE D, ANDREWS JM, ASHBY JP and WISE R, 1990. Concentrations of oral lomefloxacin in serum and bronchial mucosa. Antimicrobial agents and chemotherapy. 34(6), 1017-9 BALDWIN DR, WILKINSON L, ANDREWS JM, ASHBY JP, WISE R and HONEYBOURNE D, 1990. Concentrations of temafloxacin in serum and bronchial mucosa. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 9(6), 432-4
CHADHA D, WISE R, BALDWIN DR, ANDREWS JM, ASHBY JP and HONEYBOURNE D, 1990. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose. The Journal of antimicrobial chemotherapy. 25(6), 959-63